"The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths tha"...
- To report signs and symptoms of infusion reactions such as fever, chills, or breathing problems.
- Of the potential risks of using Erbitux during pregnancy or nursing and of the need to use adequate contraception in both males and females during and for 6 months following the last dose of Erbitux therapy.
- That nursing is not recommended during, and for 2 months following the last dose of Erbitux therapy.
- To limit sun exposure (use sunscreen, wear hats) while receiving and for 2 months following the last dose of Erbitux.
Last reviewed on RxList: 3/1/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Erbitux Information
Erbitux - User Reviews
Erbitux User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.